FDA of­fers quick thumbs up to ex­pand Dupix­en­t's atopic der­mati­tis la­bel as Re­gen­eron/Sanofi plot block­buster moves

Sanofi and Re­gen­eron have racked up an­oth­er ap­proval for their block­buster hope­ful Dupix­ent as the FDA comes through fol­low­ing a pri­or­i­ty re­view.

The IL-4/IL-13 in­hibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER